Editorial
Next generation of drug eluting stents 'Sirolimus-analogues'
EuroInterv.2005;1:13-15
Drug-eluting stents: the equalizers in treatment of bifurcational lesions
EuroInterv.2005;1:21-23
Clinical Research
1
Treatment of de novo bifurcation lesions: comparison of Sirolimus- and Paclitaxel-eluting stents
Hoye A, van Mieghem CAG, Ong ATL, Aoki J, Rodriguez-Granillo GA, Valgimigli M, Tsuchida K, Sianos G, McFadden E, van der Giessen WJ
EuroInterv.2005;1:24-30
2
Influence of technical strategies on the outcome of coronary bifurcation stenting
EuroInterv.2005;1:31-37
3
Relation between the A1166C angiotensin II type 1 receptor gene polymorphism and cardiovascular outcomes after myocardial infarction
EuroInterv.2005;1:38-42
4
Primary transcatheter closure of postinfarction ventricular septal defects with the Amplatzer septal occluder - immediate results and up-to 5 years follow-up
EuroInterv.2005;1:43-47
5
Percutaneous closure of patent foramen ovale: head-to-head comparison of two different devices
Meier J-M, Berger A, Delabays A, Girod G, Graf D, Lyon X, Roguelov C, Vogt P, Stauffer J-C, Eeckhout E
EuroInterv.2005;1:48-52
6
Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9™ eluting stent with a biodegradable polymer coating
EuroInterv.2005;1:53-57
7
A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial
Serruys PW, Ong ATL, Piek J, Neumann F-J, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC
EuroInterv.2005;1:58-65
8
In-laboratory femoral sheath removal after heparin reversal by protamine after percutaneous coronary intervention
EuroInterv.2005;1:66-69
9
Safety and feasibility of Bivalirudin with either Cypher and Taxus drug-eluting stent during percutaneous coronary intervention
Chieffo A, Melzi G, Rogacka R, Ferrari A, Airoldi F, Cosgrave J, Michev L, Montorfano M, Carlino M, Vitrella G, Biondi-Zoccai G, Colombo A
EuroInterv.2005;1:70-74
10
Critical limb ischemia: a global epidemic.A critical analysis of current treatment unmasks the clinical and economic costs of CLI
Allie D, Hebert CJ, Lirtzman M, Wyatt C, Keller V, Khan MH, Khan MA, Fail PS, Vivekananthan K, Mitran E, Allie S
EuroInterv.2005;1:75-84
11
Usefulness and clinical impact of a fractional flow reserve-targeted strategy for coronary artery stenting: FROST III, a multicenter prospective registry
Dupouy P, Gilard M, Morelle J-F, Furber A, Aptecar E, Cazaux P, Slama M, Feldman L-J, Wittenberg O, Pernès J-M, Huret B, Commeau P, Boschat J, Teiger E, Lafont A, Steg P-G, Dubois-Randé J-L, for the FROST 3 investigators
EuroInterv.2005;1:85-92
12
Microcoil embolization for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy
Iacob M, Pinte F, Tintoiu I, Cotuna L, Coroescu M, Filip S, Popa A, Cristian G, Goleanu V, Greere V, Moscaliuc I, Neagoe G, Crisan P, Garjeu A, Chiriac L, Bolohan R, Murgu V, Lobont B, Roates J, Hila G, Postolea E
EuroInterv.2005;1:93-97
13
Long-term clinical outcome after percutaneous transluminal coronary angioplasty with provisional stenting
EuroInterv.2005;1:98-104
New Devices
15
Initial clinical experience with an IVUS-guided transmembrane puncture device to facilitate recanalization of total femoral artery occlusions
EuroInterv.2005;1:115-119



